CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 250 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04684485
NCT04684485Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

Sun Pharmaceutical Industries Limited·interventional·Posted Dec 24, 2020·Updated Dec 30, 2025

In Brief

A Phase 2 clinical trial evaluating Placebo, SCD-044_Dose 1, and 2 other interventions for Dermatitis, Atopic. Completed, enrolled 250 participants across 58 sites in 5 countries.

Detailed Summary

This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesEl Salvador, Estonia, Georgia, Poland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 24, 2020
Enrollment StartJul 30, 2021
Primary CompletionNov 11, 2024
Study CompletionMar 18, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.5 years ago

Interventions

Placebodrug

Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.

SCD-044_Dose 1drug

SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.

SCD-044_Dose 2drug

SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.

SCD-044_Dose 3drug

SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.